RNA Disease Diagnostics Announces Inaugural Joint Meeting of Expanded Board of Directors and Advisory Board RNA Disease Diagnostics Inc. New York, New York, UNITED STATES
BALTIMORE, May 11, 2021 (GLOBE NEWSWIRE) RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that it held an inaugural joint meeting of its Board of Directors and Advisory Board on May 10, 2021. The newly expanded Board of Directors and Advisory Board will work alongside the leadership team to advance RNADD s proprietary
Antisense RNA diagnostic platform to prevent the transmission of infectious diseases. We are honored to have such a highly skilled, well-regarded group of industry veterans to comprise our Board of Directors and Advisory Board, said Allan Oberman, co-Founder and Chairman of RNADD. Representing decades of experience in healthcare, finance, business, and more,
Published: May 11, 2021
BALTIMORE, May 11, 2021 (GLOBE NEWSWIRE) RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that it held an inaugural joint meeting of its Board of Directors and Advisory Board on May 10, 2021. The newly expanded Board of Directors and Advisory Board will work alongside the leadership team to advance RNADD s proprietary
Antisense RNA diagnostic platform to prevent the transmission of infectious diseases. We are honored to have such a highly skilled, well-regarded group of industry veterans to comprise our Board of Directors and Advisory Board, said Allan Oberman, co-Founder and Chairman of RNADD. Representing decades of experience in healthcare, finance, business, and more, they will be instrumental as we execute on our strategy to deliver lab-based, point-of-care and home-use diagnostics for the affordable, rapid detection of COVID-19 and be
/PRNewswire/ Exactly one year after releasing its first-ever Climate Action Plan, today the City of Houston is ushering in a new chapter for the energy.
Search jobs 06-May-2021 Evotec launches beLAB1407 to accelerate translational research from the UK s academic life science ecosystem in collaboration with Bristol Myers Squibb
DGAP-News: Evotec SE / Key word(s): Miscellaneous
06.05.2021 / 07:30
beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
THE COLLABORATION LEVERAGES EVOTEC S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR
Hamburg, Germany, 06 May 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from
Share
“Meeting with the students [virtually] to discuss the challenges I had prepared was so inspiring because I saw the interest in science sparking during our conversations,” reflects Erick Eguia, a junior studying brain and cognitive sciences. Eguia had the unique experience of taking part in a longstanding MIT International Science and Technology Initiatives (MISTI) program in a new way over Google Classroom to a group of eager students in Spain.
Typically during Independent Activities Period (IAP), MIT-Spain’s Global Teaching Labs (GTL) Program sends over 40 students to high schools across Spain and Andorra to share MIT’s hands-on approach to STEM education. MIT students are, in turn, able to experience the diverse culture of Spain as well as practice their teaching, presentation, language, and problem-solving skills.